

# *Williamsburg BioProcessing Foundation*

## **Viral Vectors & Vaccines**

*Process Development and Production Issues*

*November 14–16, 2005*

### *12th Annual Meeting*

#### **Sunday, November 13**

4:00–6:00 pm: **Registration, Welcome Reception (Exhibit and Poster Setup)**

#### **Monday, November 14**

7:00–8:00 am: **Registration and Continental Breakfast — Meeting Room Foyer**

8:00–8:30 am: **Introduction**

Keith L. Carson — *Conference Chairman*

8:30–9:15 am: **Manufacture and Control of ImmunoVEX<sup>Trimelan</sup> - An Autologous Dendritic Cell Vaccine Transduced with an HSV Vector**

Colin Love — *BioVex*

9:15–10:00 am: **Process Development, Scale-up and Clinical Manufacturing of AlphaVaccines**

Todd L. Talarico, Ph.D. — *AlphaVax, Inc.*

10:00–10:30 am: **Break — Exhibit Area**

10:30–11:15 am: **An Inactivating Instability Pathway of High-Titer Adenoviral Vectors in Liquid Formulations**

David Frey — *Cell Genesys, Inc.*

11:15–Noon: **Assuring Biological Activity of an Adenovirus-Based HIV Vaccine**

Katherine Einterz-Owen, Ph.D. — *Merck & Co.*

Noon–1:30 pm: **Lunch — Exhibit Area**

1:30–2:15 pm: **Gene Therapy and the Critical Path—CBER Approaches to Identifying and Responding to Potential Roadblocks**

Maritza McIntyre, Ph.D. — *Division of Cellular and Gene Therapies, CBER, FDA*

2:15–3:00 pm: **Process Development for the Upstream Medium Exchange and Downstream Purification of Adenovirus Product Candidates Used in Vaccine Production**

Halima Namatovu — *GenVec, Inc.*

3:00–3:30 pm: **Break — Exhibit Area**

3:30–4:15 pm: **Overcoming the Enablement Challenge in the Development and Manufacture of Viral Vectors**

Madhusudan Peshwa, Ph.D. — *Maxcyte, Inc.*

4:15–5:00 pm: **Development of a Venezuelan Equine Encephalitis Virus (VEEV) Replicon-Based Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Genital Infection**

Deborah Long, Ph.D. — *Wyeth Vaccines Research*

5:00–5:45 pm: **A Highly Productive rHSV-Based rAAV Manufacturing Process**

David R. Knop, Ph.D. — *Applied Genetic Technologies Corporation*

6:00–7:30 pm: **Reception — Exhibit Area**

*Due to circumstances beyond the control of the conference organizers, the program is subject to change.*

# *Williamsburg BioProcessing Foundation*

## **Viral Vectors & Vaccines**

*Process Development and Production Issues*

*November 14–16, 2005*

### **Tuesday, November 15**

- 7:30–8:30 am: **Continental Breakfast** — *Exhibit Area*
- 8:30–9:15 am: **NIAID's Role in Influenza Product Development**  
David Cho, Ph.D. — *Infl uenza, SARS, & Related Viral Respiratory Diseases Section, RDB / DMID / NIAID / NIH*
- 9:15–10:00 am: **Developing a Cell Culture Process for Production of a Live Attenuated Influenza Virus Vaccine in Madin Darby Canine Kidney Cells**  
Ajit Subramanian, Ph.D. — *Medimmune Vaccines*
- 10:00–10:30 am: **Break** — *Exhibit Area*
- 10:30–11:15 am: **Hemagglutinin Quantification and Identification of Influenza A&B Strains Propagated in PER.C6 Cells: A Novel RP-HPLC Method**  
Hans Kapteyn, Ph.D. — *Crucell Corporation*
- 11:15–Noon: **Analytical and Biological Characterization of Supercoiled Plasmids Purified by Various Chromatographic Techniques**  
Anthony Green, Ph.D. — *Puresyn, Inc.*
- Noon–6:00 pm: *Free Afternoon with Recommended Activities*
- 6:00–9:00 pm: **Conference Banquet**

### **Wednesday, November 16**

- 7:30–8:30 am: **Continental Breakfast** — *Exhibit Area*
- 8:30–10:00 am: **Technical Workshops I**
- 10:00–10:30 am: **Break** — *Exhibit Area*
- 10:30–Noon: **Technical Workshops II**
- Noon–1:30 pm: **Lunch** — *Exhibit Area*
- 1:30–2:15 pm: **CMC Challenges in the Development of Viral Vaccines**  
Suman Patel, Ph.D. — *Therion Biologics Corporation*
- 2:15–3:00 pm: **Engineering Solutions to the Manufacture of Adenoviral-Based Pharmaceuticals**  
Shuyuan Zhang, Ph.D. — *Introgen Therapeutics, Inc.*
- 3:00–3:30 pm: **Break** — *Exhibit Area (Exhibit & Poster Teardown at 3:30 pm)*
- 3:30–4:15 pm: **Lentiviral Vector Manufacture**  
Boro Dropulic, Ph.D. — *Lentigen Corporation*
- 4:15–5:00 pm: **Innovations in Vaccine Delivery and Stabilization**  
Mary Pat Moyer, Ph.D. — *INCELL Corporation, LLC*
- 5:00–5:45 pm: **Guidelines for Protecting Intellectual Property: An In-Company Perspective**  
David Parker, Ph.D., J.D. — *Introgen Therapeutics, Inc.*